Obinutuzumab for the treatment of lymphoproliferative disorders

Bibliography

• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase III trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2003;21:1746-51
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43
   PubMed Web of Science ®Google Scholar
• Racila E, Link BK, Weng WK, A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14:6697-703
   PubMed Web of Science ®Google Scholar
• Bannerji R, Kitada S, Flinn IW, Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003;21:1466-71
   PubMed Web of Science ®Google Scholar
• Dalle S, Reslan L, Besseyre de Horts T, Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10:178-85
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, Mechanism of action of type 2, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186:3762-9
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7
   PubMed Web of Science ®Google Scholar
• Cittera E, Leidi M, Buracchi C, The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 2007;178:6616-23
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type 1/2 distinction of CD20 antibodies. Blood 2011;118:358-67
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM, A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: southwest Oncology Group Protocol S9911. Blood 2003;102:1606-12
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203-16
   PubMed Web of Science ®Google Scholar
• Pedersen AE, Jungersen MB, Pedersen CD. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology 2011;133:239-45
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916-24
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
   PubMed Web of Science ®Google Scholar
• Boyd RS, Jukes-Jones R, Walewska R, Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009;8:1501-15
   PubMed Web of Science ®Google Scholar
• Meyer zum Buschenfelde C, Feuerstacke Y, Gotze KS, GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res 2008;68:5414-22
   PubMed Web of Science ®Google Scholar
• Klepfish A, Gilles L, Ioannis K, Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009;1173:865-73
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, FcgammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcgammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550-60
   PubMed Web of Science ®Google Scholar
• Goteri G, Olivieri A, Ranaldi R, Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol 2006;19:421-31
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type 2 anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, Novel type 2 anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519-29
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73
   PubMed Web of Science ®Google Scholar
• Herter S, Waldhauer I, Otz T. Superior efficacy of the novel type 2, glycoengineered CD20 antibody GA101 vs. the type 1 CD20 antiobodies rituximab and ofatumumab. ASH Annual Meeting Abstracts. Blood 2010;116:3925
   Google Scholar
• Ivanov A, Beers SA, Walshe CA, Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59
   PubMed Web of Science ®Google Scholar
• Jak M, van Bochove GG, Reits EA, CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type 2 anti-CD20 monoclonal antibody GA101. Blood 2011;118:5178-88
   PubMed Web of Science ®Google Scholar
• Herting F, Bader S, Umana P, Klein C. Enhanced activity of GA101, a novel type 2, glycoengineered CD20 antibody, in combination wtih bendamustine or fludarabine, and with the Bcl-2 family inhibitors ABT-737 or ABT-263. ASH Annual Meeting Abstracts. Blood 2010;116(21):3915a
   Google Scholar
• Salles GA, Morschhauser F, Lamy T, Phase I study of R05072759 (GA101) in patients with relapsed/refractory CD20+ non-Hogkin lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 2009;114(22):1704a
   Google Scholar
• Morschhauser F, Cartron G, Lamy T, Phase I study of R05072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2009;114(22):884a
   Google Scholar
• Sehn LH, Assouline SE, Stewart DA, A phase I study of GA101 (R05072759) monotherapy followed by maitenance in patients with multiply relapsed/refractory CD20+ malignant disease. ASH Annual Meeting Abstracts. Blood 2009;114(22):934a
   PubMedGoogle Scholar
• Davies A, Radford J, Cartron G, Interim results from a phase IB study of the anti-CD20 antibody obinutuzumab (GA101) in combination with FC or CHOP in relapsed/refractory follicular lymphoma (FL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0368a
   Google Scholar
• Salles GA, Morschhauser F, Thieblemont C, Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients – updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). ASH Annual Meeting Abstracts. Blood 2010;116(21):2868a
   Google Scholar
• Sehn LH, Goy A, Offner FC, Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Preliminary Analysis of the GAUSS study. ASH Annual Meeting Abstracts. Blood 2011;118(22):269a
   Google Scholar
• Cartron G, Thieblemont C, Solal-Celigny P, Results from a phase II study (B020999) of R05072759 (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. International Conference on Malignant Lymphoma. Ann Oncol 2011;22(s4):144a
   Google Scholar
• Morschhauser F, Salles G, Cartron G, Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) - a rational approach. European Hematology Association Annual Congress. Haematologica 2011;96(s2):0935a
   Google Scholar
• Cartron G, Morshhauser F, Thieblemont C, Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0101a
   Google Scholar
• Goede V, Fischer K, Raymonde B, Chemoimmunotherapy with chlorambucil and the type 2 CD20 antibody GA101 in patients with chronic lymphocytic leukemia and comorbidity: results of the run-in phase of the CLL11 (B021004) trial. ASH Annual Meeting Abstracts. Blood 2010;116(21):1387a
   Google Scholar
• Cartron G, Blasco H, Paintaud G, Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43-52
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Held G, Zeynalova S, Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). ASH Annual Meeting Abstracts. Blood 2011;118(22):592a
   Google Scholar
• Stolz C, Schuler M. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009;50:873-85
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816-24
   PubMed Web of Science ®Google Scholar
• Zayen A, Rais H, Rifi H, Rituximab-induced interstitial lung disease: case report and literature review. Pharmacology 2011;87:318-20
   PubMed Web of Science ®Google Scholar